Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response [Valutazione di efficacia di Rituximab al dosaggio di 500mg e.v., 2 infusioni a distanza di 2 settimane, in confronto al dosaggio standard di 1000mg e.v., 2 infusioni a distanza di 2 settimane nel mantenimento della buona risposta clinica in pazienti affetti da artrite reumatoide, gia trattati con Rituximab al dosaggio standard per almeno 2 cicli]

Trial Profile

Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response [Valutazione di efficacia di Rituximab al dosaggio di 500mg e.v., 2 infusioni a distanza di 2 settimane, in confronto al dosaggio standard di 1000mg e.v., 2 infusioni a distanza di 2 settimane nel mantenimento della buona risposta clinica in pazienti affetti da artrite reumatoide, gia trattati con Rituximab al dosaggio standard per almeno 2 cicli]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top